SCREENING

RECOMMENDATION

All patients 65 or older should be asked about their use of alcohol at least annually, to identify problem drinking.

RATIONALE

About half of the > 65 population drinks alcohol; 2-4% may have abuse or dependence ("alcoholism").

Older adults have higher blood alcohol levels per amount consumed than do younger adults, due to decreased gastric alcohol dehydrogenase and lower volume of distribution.

Aging may increase sensitivity to alcohol, particularly in the central nervous system.

90% of older adults use medications, and as many as 100 may interact adversely with alcohol.

- Alcohol combined with H2 blockers, aspirin may raise alcohol levels
- Benzodiazepines, tricyclic antidepressants, narcotics, barbiturates, antihistamines may increase sedation, impair psychomotor function
- Aspirin, NSAIDs may increase bleeding time and cause gastric inflammation and bleeding
- Metronidazole, sulfonamides, oral hypoglycemics (tolbutamide, chlorpropamide) may cause disulfiram-like response, with nausea/vomiting
- Reserpine, aldomet, nitroglycerine, hydralazine may produce hypotension
- Acetaminophen, isoniazid, phenylbutazone may increase hepatotoxicity
- Antihypertensives, antidiabetic drugs, drugs for ulcers, gout, and heart failure may exacerbate the underlying disease
- Benzodiazepines, narcotics, barbiturates, warfarin, propranolol, isoniazid, and tolbutamide may alter drug metabolism

SPECIAL ATTENTION TO THE PATIENT WHO USES MORE THAN ONE SUBSTANCE

Be aware of use of other potentially addictive substances in addition to alcohol (prescription drugs like sedatives or narcotic analgesics, illicit drugs, nicotine); they may interact/reinforce each other.

Added expertise with diagnosis and management, and inpatient treatment may be needed.

CLINICAL CLUES

Memory loss, cognitive impairment

Depression, anxiety
Neglect of hygiene, appearance

Poor appetite, nutritional deficits

Sleep disruption

Hypertension refractory to therapy

Blood sugar control problems

Seizures refractory to therapy

Impaired balance and gait, falls

Recurrent gastritis and esophagitis

---

**WHAT TO ASK FIRST**

"Tell me about your use of alcohol, including any beer, wine, or liquor/spirits."

**FOLLOW UP THOSE WHO HAVE HAD ANY ALCOHOL IN THE LAST YEAR, BY ASKING**

"On average, how many days per week do you drink alcohol?"

"On a typical day when you drink, how many drinks do you have?"

(I drink = 72 ounces of beer, 5 ounces of wine, or 7.5 ounces of liquor/spirits)

What is the maximum number of drinks you had on any given occasion during the last month?

**THEN, ASK THE CAGE QUESTIONS**

Have you ever felt that you should Cut down on your drinking?

Have people ever Annoyed you by criticizing your drinking?

Have you ever felt Guilty about your drinking?

Have you ever had a drink (Eye opener) first thing in the morning to steady your nerves or get rid of a hangover?

**LAB TESTING**

Inadequate sensitivity/specificity for screening

Several may be useful adjuncts for corroboration:
elevated gamma-glutamyl transpeptidase (GGT), mean corpuscular volume (MCV), carbohydrate-deficient transferrin (CDT) for suspicion of heavy drinking; blood alcohol level > 100 mg/dl without intoxication may suggest tolerance

CLASSIFYING YOUR FINDINGS

CLASSIFICATION

LIGHT, SAFE DRINKING

On average, drinking £ 1 drink per day, £ 7 drinks per week, and < 3 drinks on any heavier drinking occasions; 0 CAGE score, and no evidence of dysfunction related to drinking (physical, psychological, or social), and not using medications that interact adversely with alcohol.

HEAVY AND/OR RISKY DRINKING

On average, > 1 drink per day, or > 7 drinks per week, or > 3 drinks on heavier drinking occasions; or any drinking and _ I on the CAGE, or evidence of drinking-related dysfunction, or using alcohol and medications in combinations that might interact adversely.

Possible alcohol abuse/dependence (DSM-IV)

DEPENDENCE: > 3 of the following criteria met

- Tolerance, or requiring more alcohol to get "high"
- Withdrawal, or drinking to relieve/prevent withdrawal
- Drinking in larger amounts, or for a longer period of time than intended
- Persistent desire to drink, or unsuccessful efforts to cut down or control drinking
- A lot of time spent in activities necessary to obtain or use alcohol or recover from effects
- Important occupational, social, or recreational activities given up or reduced due to drinking
- Drinking continues despite knowledge of persistent/recurrent physical or psychological problems likely to be caused/worsened by alcohol

ABUSE: > 1 of the following criteria met, and has never met criteria for dependence

- Recurrent drinking resulting in the failure to fulfill major obligations at work or in the home
- Recurrent drinking in situations where it is physically hazardous
- Recurrent alcohol-related legal problems
- Continued drinking despite persistent or recurrent social problems caused or worsened by alcohol

INTERVENING/Therapy

Recommendation
Counsel all non-abstainers about safe drinking, intervene if heavy/risky drinking or abuse/dependence. Be alert for dual diagnoses (i.e. drinking/depression), involve family/caregivers whenever possible but watch for enabling behavior.

**LIGHT, SAFE DRINKING**

prevent future drinking problems by periodically counseling on safe drinking

**HEAVY AND/OR RISKY DRINKING**

brief intervention to reduce risk associated with drinking

Give specific advice on safe amounts/frequency of drinking (on average, < 1 drink per day, < 7 drinks per week, < 3 drinks on heavier drinking occasions)

Counsel against concurrent drinking and use of drugs that interact with alcohol: clinician or pharmacist should advise if patient unsure of interactions

Recommend no alcohol if planning activities impaired by alcohol (driving, operating machinery, caregiving for others), give reminder that it takes about 1 hour for the body to metabolize 1 drink

Point out to patient their specific potential for alcohol-disease interactions, as incentive for following advice on controlling their drinking

Consider formal prescription or contract with patient, specifying plan to adhere to your advice

**ABUSE/DEPENDENCE**

stress the need for therapy; avoid terms like "alcoholism" or "addiction"; emphasize adverse effects of drinking on their health

**BEFORE TREATING ABUSE/DEPENDENCE**

Assessment

Psychosocial history/social support

Physical exam, psychiatric exam (consider dual diagnoses such as depression), laboratory testing

Ability to abstain from alcohol for > 5 days?

Planning

Give feedback to patient about problem, emphasize alcohol effects on their overall health

Assess interest/motivation to change
Review options for treatment

**PSYCHOSOCIAL TREATMENT OPTIONS**

Self-help groups (i.e. Alcoholics Anonymous)

Professional (i.e. psychodynamic, cognitive-behavioral, counseling, social support, family therapy, age-specific inpatient/outpatient)

**PHARMACOTHERAPY OVERVIEW**

Disulfiram - Not effective in clinical trials, limited role in older adults due to cardiac effects

Psychoactive adjuncts - clinical trials of anxiolytics and antidepressants have shown modest benefit if patients have concurrent anxiety and/or depression

Naltrexone - opioid antagonist; clinical trials (only 1 in older adults) showed it to be a relatively effective adjunct to psychosocial therapy, reducing likelihood of return to clinically significant drinking and relapse

Future agents (in clinical trials, U.S.A. or Europe) - nalmefene: like naltrexone, an opioid antagonist, but possibly greater potency and less toxicity; and acamprosate: a derivative of a GABA analogue

**USE OF NALTREXONE THERAPY**

Criteria for induction

Drinking in last 30 days, or abstinent but craving

Able to abstain for 5 days

Not in renal failure

Acceptable liver function tests (< 4 X normal)

No opioid dependence, opioid-free 7-10 days

Prior to starting treatment

Insist on patient's commitment to start psychosocial therapy (i.e. counseling and/or self-help groups)

Beginning treatment 25 mg/day for 2 days; 50 mg/day thereafter

Monitor response at least monthly, for 3 months

Review compliance with medication

Review any drinking behavior - modify counseling as appropriate, based on consumption
Review adverse effects (i.e., nausea, headache, dizziness, fatigue, insomnia, anxiety)

Repeat lab testing; discontinue if transaminases > 4 X normal or any bilirubin elevation

Assess need for further treatment at 3 months

**FOLLOW-UP**

Family/peer support critical for long-term success

Review need for maintenance counseling, for both successfully abstinent, and also refractory patients

Developed by Thomas V. Jones, MID, MPH, Univ. Of Nebraska Med. Ctr. and Omaha VAMC; with Wendy Adams, MID, Carol Joseph, MID, and the American Geriatrics Society Clinical Practice Committee
BACKGROUND AND SIGNIFICANCE

Pain is an unpleasant sensory and emotional experience. It is recognized as a complex phenomenon derived from sensory stimuli and modified by individual memory, expectations, and emotions. Unfortunately, there are no objective biological markers of pain. Therefore, the most accurate evidence of pain and its intensity is based on the patient’s description and self-report.

A concise definition of chronic pain remains difficult. For some conditions, chronic pain is defined as pain that exists beyond an expected time frame for healing. For other conditions, it is well recognized that healing may never occur. In many cases, chronic pain is understood as persistent pain that is not amenable to routine pain control methods. Because there are many differences in what may be regarded as chronic pain, the definition remains flexible and related to specific diagnoses or cases. (For a more detailed description, see the classification of chronic pain of the International Association for Study of Pain).

Chronic pain is common in older people. A recent Louis Harris telephone survey found that one in five older Americans (18%) are taking analgesic medications regularly (several times a week or more), and 63% of those had taken prescription pain medications for more than 6 months. Americans (18%) are taking analgesic medications regularly (several times a week or more), and 63% of those had taken prescription pain medications for more than 6 months.

The consequences of chronic pain among older people are numerous. Depression, sleep disturbance, impaired ambulation, and increased healthcare utilization and costs have all been associated with the presence of pain in older people. Although less thoroughly described, many other conditions are potentially worsened by the presence of pain, including gait disturbances, slow rehabilitation, and adverse effects from multiple drug prescriptions.

Psychosocial factors are known to be associated with pain in older patients. Keefe et al. (1987) have shown that older adults with good coping strategies have significantly lower pain and psychological disability. Depression is often associated with pain in the older patient. Parmelee et al. (1991) showed a statistically significant correlation between pain and depression among nursing home residents even after controlling for self-reported functional status and physical health. Older patients with cancer pain rely heavily on family and informal caregivers. For these patients and caregivers, pain can be a metaphor for death, resulting in substantial suffering.

Classifying chronic pain in pathophysiologic terms may help the clinician select therapy and determine prognosis. Treatment strategies targeted specifically to underlying pain mechanisms are likely to be most effective. Although it is beyond the scope of this guideline to describe the pathophysiology of individual pain syndromes in detail, most syndromes can be classified into four basic categories. This classification system, with examples, is shown in Table 1. Nociceptive pain may be visceral or somatic and is most often derived from stimulation of pain receptors. Nociceptive pain may arise from tissue inflammation, mechanical deformation, ongoing injury, or destruction. Examples include inflammatory or traumatic arthritis, myofascial pain syndromes, and ischemic disorders. Nociceptive mechanisms usually respond well to traditional approaches to pain management, including common analgesic medications and nonpharmacologic strategies. Neuropathic pain results from a pathophysiologic process that involves the peripheral or central nervous system. Examples include trigeminal neuralgia, post-herpetic neuralgia, poststroke central or thalamic pain, and postamputation phantom limb pain. These pain syndromes do not respond as predictably as nociceptive pain problems to conventional analgesic therapy. However, they have been noted to respond to unconventional analgesic drugs such as tricyclic antidepressants, anticonvulsants, or anti-arrhythmic drugs. Mixed or unspecified pain is often regarded as having mixed or unknown mechanisms. Examples include recurrent headaches and some vasculitic pain syndromes. Treatment of these syndromes is more unpredictable and may require various trials of different or combined approaches. Finally, when psychological factors are judged to have a major role in the onset, severity, exacerbation, or...
Table 1. Pathophysiologic Classification of Chronic Pain

<table>
<thead>
<tr>
<th>Nociceptive pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthropathies (e.g., rheumatoid arthritis, Osteoarthritis, gout, posttraumatic arthropathies, mechanical neck and back syndromes)</td>
</tr>
<tr>
<td>Myalgia (e.g., myofascial pain syndromes)</td>
</tr>
<tr>
<td>Skin and mucosal ulcerations</td>
</tr>
<tr>
<td>Nonarticular inflammatory disorders (e.g., polymyalgia rheumatica)</td>
</tr>
<tr>
<td>Ischemic disorders</td>
</tr>
<tr>
<td>Visceral pain (pain of internal organs and viscera)</td>
</tr>
<tr>
<td>Neuropathic pain</td>
</tr>
<tr>
<td>Postherpetic neuralgia</td>
</tr>
<tr>
<td>Trigeminal neuralgia</td>
</tr>
<tr>
<td>Painful diabetic polyneuropathy</td>
</tr>
<tr>
<td>Post-stroke pain (central pain)</td>
</tr>
<tr>
<td>Postamputation pain</td>
</tr>
<tr>
<td>Myelopathic or radiculopathic pain (e.g., spinal stenosis, arachnoiditis, root sleeve fibrosis)</td>
</tr>
<tr>
<td>Atypical facial pain</td>
</tr>
<tr>
<td>Causalgia-like syndromes (complex regional pain syndromes)</td>
</tr>
<tr>
<td>Mixed or undetermined pathophysiology</td>
</tr>
<tr>
<td>Chronic recurrent headaches (e.g., tension headaches, migraine headaches, mixed headaches)</td>
</tr>
<tr>
<td>Vasculopathic pain syndromes (e.g., painful vasculitis)</td>
</tr>
<tr>
<td>Psychologically based pain syndromes</td>
</tr>
<tr>
<td>Somatization disorders</td>
</tr>
<tr>
<td>Hysterical reactions</td>
</tr>
</tbody>
</table>

Persistence of pain, this is described as psychogenic pain. Examples may include conversion reactions and somatoform disorders. Patients with these disorders may benefit from specific psychiatric treatments, but traditional medical interventions for analgesia are not indicated.

Age-associated changes in pain perception have been a topic of interest ever since older adults have been observed to present with unusually painless manifestations of common illness. Neuroanatomic and neurochemical findings have shown that the perception of pain and its modulation in the central nervous system are extremely elaborate and complex. Unfortunately, little is known about the effect of age alone on most of these complex neural functions. Although there may be altered transmission along A-delta and C nerve fibers associated with aging, it is not clear how this might affect an individual’s experience of pain. Experimental studies of pain sensitivity and pain tolerance across all ages (young and old persons) have had mixed results. In the final analysis, age-related changes in pain perception are probably not clinically significant.

The most common strategy for pain management is the use of analgesic drugs. Unfortunately, older patients have commonly been systematically excluded from clinical trials of such drugs. In a 1993 report of 83 randomized trials of nonsteroidal anti-inflammatory drugs (NSAIDs), which included nearly 10,000 subjects, only 2.3% were aged 65 or older and none were aged 85 or older. Although older people are more likely to experience the side effects of analgesic medications, they also appear to be more sensitive to analgesic properties, especially those of opioid analgesics. For example, single-dose studies comparing younger and older subjects with postoperative and chronic cancer pain have observed higher peak pain relief and longer duration of action among older subjects for morphine and other opioid drugs.

The use of opioid analgesic drugs for chronic non-cancer-related pain remains controversial. Reluctance to prescribe these drugs has probably been overinfluenced by political and social pressures to control illicit drug use among people who take these medications for emotional rather than medical reasons. However, addictive behavior among patients taking opioid drugs for medical indications appears to be very low. This is not to suggest that morphine and other opioid drugs should be used indiscriminately but only that fear of addiction and other side effects does not justify failure to treat severe pain, especially in those near the end of life.

GUIDELINE DEVELOPMENT PROCESS AND METHODS

The American Geriatrics Society has published position papers on the care of patients near the end of life. In these publications the Society has promoted the goals of comfort and dignity for all patients near the end of life. Inherent in these goals is the obligation of clinicians to provide effective pain management in all cases, even if doing so may hasten death by a few hours or days.

Clinical practice guidelines have been published by the Agency for Health Care Policy and Research to address the management of acute and postoperative pain, the management of cancer pain, and the management of acute back pain. Guidelines have also been published by the American Pain Society on analgesic medication for acute pain and cancer pain. These guidelines have been broad in scope, but they generally have not included considerations that are unique to the care of older patients. Treatment for chronic non-cancer-related pain has often been neglected, especially among those with nonterminal illness. Alternative care settings such as nursing homes and homes also present unique challenges about which previous guidelines have not been especially sensitive.

This project was organized to develop clinical practice guidelines specifically for the management of chronic non-cancer-related pain in older persons. The goals were to provide the reader with an overview of broad principles of chronic pain management as they apply specifically to older people and with specific recommendations to aid in decision making about pain management for this population. This is not meant to be an exhaustive, academic treatise on the subject but, rather, a practical and usable guide for clinicians so that they may rapidly upgrade their skills in the management of chronic pain problems common in the geriatric population. We have tried to avoid duplication of the work of previous guideline panels. These guidelines focus on issues that are unique to the geriatric population and on areas that have been omitted or less well developed in previous publications. We hope that our efforts will be helpful to clinicians in practice as well as to researchers and policy makers. Ultimately, we hope the beneficiaries of this work will be our patients who require effective pain management to maintain their dignity and quality of life.

The recommendations that follow are largely derived from consensus among a panel of experts from the fields of...
geriatrics, pain management, psychology, pharmacology, and nursing. After an extensive search of the medical literature for data-based publications on the subject of pain in older (or aged) persons, members of the panel abstracted and reviewed the reports. It is important to note that existing evidence-based literature on the assessment and management of chronic pain—specifically in older people—was found to be very limited in sample and design. Much of the literature presented chronic pain in a disease-specific approach, and the number of pain-producing diseases studied was very large. Few randomized clinical trials were identified, and meta-analyses were nonexistent. Outcome data were not adequate to suggest definitive algorithms in most clinical situations. Panel members sometimes drew on data derived from studies of younger patients that could be extrapolated reasonably to older persons. However, data-based literature describing chronic pain in younger populations could not always be extrapolated easily to the oldest old or to the alternative care settings where older patients are often encountered. Once the literature review was completed, panel members formulated recommendations and then reassessed them to produce the set of recommendations for external review by a variety of experts from other organizations with interest in this subject.

Many issues in chronic pain management are beyond the scope of this limited project and so are not addressed by guideline recommendations. Clearly, a number of barriers still stand in the way of the improvement of pain management in clinical practice; these barriers often involve larger issues of medical education, attitudes, medical economics, law, and health systems organization. We hope that this initial work will stimulate others to collaborate, study, revise, and develop new solutions for the significant issues not addressed by this panel.

The guidelines for improving clinical practice have been divided into four sections: Assessment of Chronic Pain in Older Persons, Pharmacologic Treatments of Chronic Pain in Older Persons, Nonpharmacologic Strategies for Pain Management in Older Persons, and Recommendations for Health Systems That Care for Older Persons. For each section, general principles are presented with specific references provided, followed by the panel’s recommendations for improving clinical assessment and management of chronic pain in older persons.

**ASSESSMENT OF CHRONIC PAIN IN OLDER PERSONS**

**General Principles**

A thorough initial assessment is crucial to understanding the causes and pathophysiology of chronic pain in the older adult.52 Pain management is most successful when the underlying cause of pain is identified and treated definitively. Inherent in the assessment of chronic pain is the need to evaluate acute pain that may indicate new concurrent illness and to distinguish this from exacerbations of chronic pain. Among those for whom the underlying cause is not remediable or only partially treatable, a multidisciplinary assessment and treatment strategy is often indicated.53 It should be remembered that there are no objective biological markers for the presence of pain. The most accurate and reliable evidence of the existence of pain and its intensity is the patient’s report.3 Even patients with mild to moderate cognitive impairment can be assessed with simple questions and screening tools.16,54–58 Health care professionals as well as family and informal caregivers must believe patients and take their reports of pain seriously.

Older patients themselves may present substantial barriers to accurate pain assessment.56 They may be reluctant to report pain despite substantial physical or psychological impairment.14 Not only do older people expect pain with aging, but they often describe discomfort, hurting, or aching rather than use the specific word pain.57 They may be reluctant to talk about pain because they may fear the need for diagnostic tests or medications that have side effects. For some patients, pain is a metaphor for serious disease or death. For others, pain and suffering represent atonement for past actions.22 Sensory and cognitive impairment, common among frail older people, make communication more difficult. Fortunately, pain can be assessed accurately in most patients by the use of techniques adapted for the individual patient’s needs and handicaps.16,58

**Specific Recommendations**

I. On initial presentation of any older person to any health care service, a health care professional should assess the patient for evidence of chronic pain.

II. Any persistent or recurrent pain that has a significant impact on function or quality of life should be recognized as a significant problem.

III. A variety of terms synonymous with pain should be used to screen older patients (e.g., burning, discomfort, aching, soreness, heaviness, tightness).

IV. For those with cognitive or language impairments, nonverbal pain behavior, recent changes in function, and vocalizations suggest pain as a potential cause (e.g., changes in gait, withdrawn or agitated behavior, moaning, groaning, or crying).

V. For those with cognitive or language impairments, reports from a caregiver should be sought.

VI. Conditions that require specific interventions should be identified and treated definitively if possible.

A. Underlying disease should be managed optimally.

B. Patients who need specialized services or skilled procedures should be referred for consultation to a healthcare specialist who has expertise in such services and procedures.

1. Patients identified as having debilitating psychiatric complications should be referred for psychiatric consultation.

2. Patients identified as abusing or as being addicted to any legal or illicit substance should be referred for consultation with an expert who has experience in pain and addiction management.

3. Patients with life-altering intractable pain should be referred to a multidisciplinary pain management center.

VII. All patients with chronic pain should undergo comprehensive pain assessment. (Figure 1 provides an example of a medical record form that can be used to summarize the initial pain assessment.59)
GERIATRIC PAIN ASSESSMENT

Date: __________       Medical Record Number __________

Patient's Name ____________________________

Problem List: __________________________________________

Medications: __________________________________________

<table>
<thead>
<tr>
<th>Pattern</th>
<th>Constant</th>
<th>Intermittant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Character</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lancinating</td>
<td>Burning</td>
<td>Stinging</td>
</tr>
<tr>
<td>Radiating</td>
<td>Shooting</td>
<td>Tingling</td>
</tr>
</tbody>
</table>

Pain Description:

<table>
<thead>
<tr>
<th>Pattern</th>
<th>Constant</th>
<th>Intermittant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Character</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lancinating</td>
<td>Burning</td>
<td>Stinging</td>
</tr>
<tr>
<td>Radiating</td>
<td>Shooting</td>
<td>Tingling</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pattern</th>
<th>Constant</th>
<th>Intermittant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Character</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lancinating</td>
<td>Burning</td>
<td>Stinging</td>
</tr>
<tr>
<td>Radiating</td>
<td>Shooting</td>
<td>Tingling</td>
</tr>
</tbody>
</table>

Pain Intensity:

<table>
<thead>
<tr>
<th>Pain Intensity</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Worst Pain in Last 24 hours:

<table>
<thead>
<tr>
<th>Worst Pain in Last 24 hours</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mood: ________________________

Depression Screening Score: ________________________

Gait and Balance Score: ________________________

Impaired Activities: ________________________

Relieving Factors: ________________________

Sleep Quality: ________________________

Bowel Habits: ________________________

Other Assessments or Comments: ________________________

Other Assessments or Comments: ________________________

Other Assessments or Comments: ________________________

Most Likely Cause of Pain: ________________________

Plans: ________________________

Figure 1. Example of a medical record form that can be used to summarize pain assessment in older persons.\textsuperscript{59}
A. Comprehensive pain assessment should include a medical history and physical examination, as well as a review of the results of the pertinent laboratory and other diagnostic tests, with the goals of recording a temporal sequence of events that led to the present pain complaint and establishing a definitive diagnosis, plan for care, and likely prognosis.

B. Initial evaluation of the present pain complaint should include characteristics such as intensity, character, frequency (or pattern, or both), location, duration, and precipitating and relieving factors.

C. Initial evaluation should include a thorough analgesic medication history, including current and previously used prescription medications, over-the-counter medications, and “natural” remedies. The effectiveness and any side effects of current and previously used medications should be recorded.

D. Initial evaluation should include a comprehensive physical examination with particular focus on the neuromuscular system (e.g., search for neurologic impairments, weakness, hyperalgesia, hyperpathia, allodynia, numbness, paresthesia) and the musculoskeletal system (e.g., palpation for tenderness, inflammation, deformity, trigger points).

E. Initial evaluation should include evaluation of physical function.
   1. Evaluation of physical function should include a focus on pain-associated disabilities, including activities of daily living (e.g., Katz ADLs, Lawton IADLs, FIM, Barthel Index).
   2. Evaluation of physical function should include performance measures of function (e.g., range of motion, Up-and-Go Test, Tinetti Gait and Balance Test).

F. Initial evaluation should include evaluation of psychosocial function.
   1. Evaluation of psychosocial function should include assessment of the patient’s mood, especially for depression (e.g., a geriatric depression scale, CES-D scale).
   2. Evaluation of psychosocial function should include assessment of the patient’s social networks, including any dysfunctional relationships.

G. A quantitative assessment of pain should be recorded by the use of a standard pain scale (e.g., visual analogue scale, word descriptor scale, numerical scale) (see Figure 2).

   1. Patients with cognitive or language barriers should be presented with scales that are tailored for their needs and disabilities (e.g., scales adapted for speakers of a foreign language, scales in large print, or scales for the visually impaired that do not require visual-spatial skills).
   2. Quantitative estimates of pain based on clinical impressions or surrogate reports should not be used unless the patient is unable to reliably make his or her needs known.

VIII. Patients with chronic pain and their caregivers should be instructed to use a pain log or pain diary with regular entries for pain intensity, medication use, response to treatment, and associated activities. (Figure 3 provides an example of a medical record form that can be used as a pain diary or to record pain assessments over time).

IX. Patients with chronic pain should be reassessed regularly for improvement, deterioration, or complications attributable to treatment. The frequency of follow-up should be a function of the severity of the pain syndrome and the potential for adverse effects of treatment.

   A. Reassessment should include evaluation of significant issues identified in the initial evaluation.
   B. The same quantitative assessment scales should be used for follow-up assessments.
   C. Reassessment should include an evaluation of analgesic medication use, side effects, and adherence problems.
   D. Reassessment should include an evaluation of the positive and negative effects of any nonpharmacologic treatments.

PHARMACOLOGIC TREATMENT OF CHRONIC PAIN IN OLDER PERSONS

GENERAL PRINCIPLES

The most common treatment of pain in older people involves the use of analgesic drugs. All pharmacologic interventions carry a balance of benefits and burdens. The patient should be given an expectation of pain relief, but it is unrealistic to suggest or sustain an expectation of complete relief for some patients with chronic pain. The goals, expectations, and tradeoffs of possible therapies need to be discussed openly. A period of trial and error should be anticipated when new medications are initiated and while titration occurs. Review of medications, doses, use patterns, efficacy, and adverse effects should be a regular process of care, and seemingly ineffective drugs should be tapered and discontinued.

Although older people are more likely to experience adverse reactions, analgesic drugs are safe and effective for use by this population. For some classes of pain-relieving medications (opioids, for example), older patients have been shown to have increased analgesic sensitivity. However, because the older population is heterogeneous, optimum dosage and side effects are difficult to predict. Recommendations for age-adjusted dosing are not available for most analgesics. The adage “start low and go slow” is probably appropriate for most drugs known to have high side-effect profiles in the older adult. In reality, dosing for most patients requires careful titration, including frequent assessment and dosage adjustments, to optimize pain relief while monitoring and managing side effects.

Pharmacologic therapy is most effective when combined with nonpharmacologic strategies to optimize pain management. Analgesic drugs should also supplement other medications directed at definitive treatment or optimum management of underlying disease. It is recognized that there are major potential problems with multiple drug use by older patients. However, polypharmacy (the use of more than one agent to effect a therapeutic endpoint) may be necessary to minimize dose-limiting adverse effects of a particular drug.
Combining smaller effective doses of differing drug classes may produce pain relief without as much risk of the side effects associated with higher doses of a single medication. Close monitoring is important when multiple medications are prescribed, particularly for patients with concurrent medical problems.

In older patients, the chronic use of NSAIDs is associated with a high frequency of adverse effects. The risk of gastrointestinal bleeding associated with NSAID use in a general population is about 1%. For those aged 60 or older, the risk reaches 3 to 4%, and for those aged 80 or older with a history of gastrointestinal bleeding, the risk is about 9%. The relative risks and benefits of NSAIDs should be weighed carefully against other available treatments for older patients. For most patients with mild to moderate pain from degenerative joint disease, acetaminophen provides satisfactory pain relief with a much lower risk of side effects than with NSAID drugs. The concomitant administration of misoprostol, histamine2-receptor antagonists, proton pump inhibitors, and antacids is only partially successful in reducing the risk of gastrointestinal bleeding associated with NSAID use, and the side-effect profiles of these additional medications in this population must be weighed against their potential benefits. It should also be remembered that these gastrointestinal protective drugs do nothing to prevent the renal impairment and other drug-drug and drug-disease interactions commonly associated with NSAIDs. For many patients, chronic opioid therapy, low-dose corticosteroid therapy (for those with inflammatory conditions), or other adjunctive drug strategies (e.g., the use of antidepressants or anticonvulsants for neuropathic pain) may have fewer life-threatening risks than does long-term daily use of high-dose NSAIDs. Table 2 lists some examples of NSAID choices as well as acetaminophen.

The use of opioid drugs for chronic non-cancer-related pain remains controversial, but they are probably underutilized in the treatment of older people. Table 3 provides examples of some opioids used for treating chronic pain in...
**CHRONIC PAIN RECORD**

Date: __________ Medical Record Number __________

Patient's Name: ________________

Pain Medications and Directions:
________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Pain Scale Used*: __________

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Pain Intensity*</th>
<th>Activity</th>
<th>Action</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Choose an appropriate scale, indicate which scale is being used, and use the same scale for each assessment.

Figure 3. Example of a medical record form that can be used to document pain control over time. Additional columns may be added to monitor side effects or the use of other treatments.
Table 2. Acetaminophen and Nonsteroidal Anti-Inflammatory Drugs*†

<table>
<thead>
<tr>
<th>Drug</th>
<th>Maximum Dosage</th>
<th>Pharmacologic Changes</th>
<th>Precautions and Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen†‡ (Tylenol)</td>
<td>4000 mg/24 h (q 4–6 h dosing)</td>
<td>Hepatotoxic above maximum dose</td>
<td>Avoid exceeding maximum recommended dose</td>
</tr>
<tr>
<td>Aspirin‡§</td>
<td>4000 mg/24 h (q 4–6 h dosing)</td>
<td>Gastric bleeding; abnormal platelet function</td>
<td>Avoid high doses for prolonged periods of time</td>
</tr>
<tr>
<td>Ibuprofen† (Motrin, Advil, Nuprin, etc.)</td>
<td>2400 mg/24 h (q 6–8 h dosing)</td>
<td>Gastric, renal, and abnormal platelet function may be dose-dependent; constipation, confusion, and headaches may be more common in older patients</td>
<td>Avoid high doses for prolonged periods of time</td>
</tr>
<tr>
<td>Naproxen‡§ (Naprosyn)</td>
<td>1000 mg/24 h (q 8–12 h dosing)</td>
<td>Similar toxicity to ibuprofen</td>
<td>Tests for salicylate levels may be necessary occasionally to avoid toxicity</td>
</tr>
<tr>
<td>Choline magnesium trisalicylate§ (Trilisate)</td>
<td>5500 mg/24 h (q 8–12 h dosing)</td>
<td>Prolonged half-life of 8–12 h; similar toxicity to ibuprofen; classic salicylate toxicity may develop at high dose</td>
<td></td>
</tr>
</tbody>
</table>

*Limited number of representative examples only for demonstrative purposes. Comprehensive lists of other classes of NSAIDs and a multitude of brand names can be located elsewhere. There is no evidence of increased efficacy or decreased adverse effects (other than specific allergic sensitivities) to warrant the extremely high costs of most proprietary variations.
†Clinicians should monitor the literature closely for availability and cost-risk-benefit analyses of the cyclo-oxygenase-2-inhibitor class of NSAIDs, which should be commercially available soon.
‡Available in liquid form.
§Available in suppository form.
Minimum platelet dysfunction.
breakthrough pain.
and when supplemented by other specific analgesic drugs for their particular needs and life styles. Clinical endpoints must be remembered that non-opioid drugs are often only partially successful and rarely provide complete relief. They are not classified formally as analgesics but found to be helpful (i.e., they reduce pain in certain intractable pain syndromes). Anticonvulsants (e.g., carbamazepine) have also been demonstrated to be helpful in certain conditions. Antidepressants and anticonvulsants may be the primary pharmacologic intervention in certain situations. The term “adjuvant” is often used for drugs that help certain kinds of pain medications. The so-called adjuvant analgesic drugs are medications for pharmacologic interventions and when supplemented by other specific analgesic drugs for their particular needs and life styles. Clinical endpoints should have some flexibility in designing regimens for managing pain, especially when used for baseline pain management and should enter into decision-making processes. Economic issues do play a major role in current pain management and should enter into decision-making processes.

The dose of opioid analgesic medications needed for the treatment of non-cancer-related chronic pain is often exaggerated. The dose of opioid analgesic medications needed for the treatment of non-cancer-related chronic pain is often exaggerated. The prevalence of narcotic abuse among older people is not known, but those aged 60 or older account for less than 1% of patients attending methadone maintenance programs. Fears of drug dependency and addiction are often exaggerated.

The doses of opioid analgesic medications needed for the treatment of non-cancer-related chronic pain are often exaggerated. The doses of opioid analgesic medications needed for the treatment of non-cancer-related chronic pain are often exaggerated.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Oral Equivalent</th>
<th>Starting Dosage</th>
<th>Aging Effects</th>
<th>Precautions and Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short-acting drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine sulfate (Roxanol, MSIR)</td>
<td>30 mg</td>
<td>15–30 mg q 4 h</td>
<td>Intermediate half-life; older people are more sensitive than younger people to side effects</td>
<td>Start low and titrate to comfort; continuous use for continuous pain; intermittent use for episodic pain; anticipate and prevent side effects</td>
</tr>
<tr>
<td>Codeine (plain codeine, Tylenol with codeine, other combinations)</td>
<td>120 mg</td>
<td>30–60 mg q 4–6 h</td>
<td>Acetaminophen-NSAID* combinations limit dose; constipation is a major issue</td>
<td>Begin bowel program early; do not exceed recommended maximum dose</td>
</tr>
<tr>
<td>Hydrocodone (Vicoden, Lortab, others)</td>
<td>30 mg</td>
<td>5–10 mg q 3–4 h</td>
<td>Acetaminophen-NSAID* combinations limit dose; toxicity similar to morphine</td>
<td>Anticipate and prevent side effects; begin bowel program early; do not exceed recommended maximum dose</td>
</tr>
<tr>
<td>Oxycodone (Roxicodone, Oxy IR, Percodan, Tylox, Percocet)</td>
<td>20–30 mg</td>
<td>5–10 mg q 3–4 h</td>
<td>Acetaminophen-NSAID* combinations limit dose; toxicity similar to morphine; oxycodone is available as a single agent</td>
<td>Anticipate and prevent side effects; begin bowel program early; do not exceed recommended maximum dose</td>
</tr>
<tr>
<td>Hydromorphone (Dilaudid)</td>
<td>7.5 mg</td>
<td>1.5 mg q 3–4 h</td>
<td>Half-life may be shorter than morphine (3 h); toxicity similar</td>
<td>Similar to morphine; start low and titrate to comfort; give continuously (q 3–4 h) for continuous chronic pain disorders</td>
</tr>
<tr>
<td><strong>Long-acting drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sustained-release* morphine (MS Contin, Kadian, Oramorph SR)</td>
<td>30 mg</td>
<td>15–30 mg q 12 h or 24 h equivalent of total prior analgesics in divided doses q 12 h</td>
<td>Rarely requires more frequent dosing than recommended on package insert</td>
<td>Escalate dose slowly because of possible drug accumulation; immediate-release opioid analgesic often necessary for breakthrough pain</td>
</tr>
<tr>
<td>Sustained-release* oxycodone (Oxycontin)</td>
<td>20–30 mg</td>
<td>10–20 mg q 12 h or 24 h equivalent of total prior analgesics in divided doses q 12 h</td>
<td>Similar to sustained-released morphine</td>
<td>Immediate-release opioid often necessary for breakthrough pain</td>
</tr>
<tr>
<td>Transdermal fentanyl (Duragesic)</td>
<td>NA (see package insert)</td>
<td>&gt;25 µg/h not recommended in opioid-naive patients</td>
<td>Effective activity may exceed 72 h in older patient (transdermal patches designed for 3-day duration of action)</td>
<td>Titrate slowly using immediate-release analgesics for breakthrough pain; peak effects of first dose may take 18–24 h</td>
</tr>
</tbody>
</table>

*These preparations are not to be broken, crushed, or dissolved. They must be used as formulated to provide continuous-release activity.

1Every 24 hour dosing.
2Every 8–12 hour dosing.
3Capsules can be opened and contents sprinkled on applesauce for easier ingestion without altering activity of the drug.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Starting Dose (po)</th>
<th>Specific Indications</th>
<th>Pharmacologic Changes</th>
<th>Precautions and Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticosteroids (prednisone)</td>
<td>2.5–5.0 mg daily</td>
<td>Inflammatory disease</td>
<td>Increased risk of hyperglycemia, osteopenia, and Cushing phenomenon</td>
<td>Avoid high dose for long-term use</td>
</tr>
<tr>
<td>Antidepressants (amitriptyline, desipramine, doxepin, imipramine, nortriptyline)</td>
<td>10 mg HS</td>
<td>Neuropathic pain, sleep disturbance</td>
<td>Increased sensitivity to side effects, especially anticholinergic effects</td>
<td>Monitor carefully for anticholinergic adverse effects; desipramine may be as effective as amitriptyline with fewer side effects; start at lowest available dose, 10 mg, and titrate HS dose upward by 10 mg every 3-5 days</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clonazapam</td>
<td>0.25–0.5 mg</td>
<td>Neuropathic pain</td>
<td>Can cause somnolence, ataxia, dizziness, leukopenia, thrombocytopenia, and rarely aplastic anemia</td>
<td>Start at 100 mg qd, increase slowly bid, 200 mg qd, then bid; check LFTs, CBC, RF at baseline; CBC at 2 then 8 weeks</td>
</tr>
<tr>
<td>Carbamazepine (Tegretol)</td>
<td>100 mg</td>
<td>Only for lancinating pain, e.g., trigeminal neuralgia</td>
<td></td>
<td>Start with low dose (100 mg) and titrate up slowly to effect; neuropathic doses not yet established; titrate to tid dosing; monitor for idiosyncratic side effects, e.g., ankle swelling, ataxia; dose range for efficacy anecdotally reported 100–800 mg tid</td>
</tr>
<tr>
<td>Gabapentin (Neurontin)</td>
<td>100 mg</td>
<td>Neuropathic pain</td>
<td>May prove to have less serious side effects than carbamazepine</td>
<td></td>
</tr>
<tr>
<td>Anti-arrhythmics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexiletine (Mexitil)</td>
<td>150 mg</td>
<td>Neuropathic pain</td>
<td>Side effects such as tremor, dizziness, unsteadiness, paresthesias are common; rarely hepatic damage and blood dyscrasias occur</td>
<td>Avoid use in patients with pre-existing heart disease; start with low dose and titrate slowly; recommend initial and follow-up ECGs; titrate to tid-qid dosing</td>
</tr>
<tr>
<td>Local Anesthetics (intravenous) Lidocaine</td>
<td>3–5 mg/kg infused every 15–30 minutes</td>
<td>Diagnostic test</td>
<td>Delirium common</td>
<td>May be useful predictor of response to mexiletine or other oral local anesthetics for neuropathic pain; diagnostic test only in a monitored environment where seizure, delirium, airway control, and hemodynamic alterations can be managed</td>
</tr>
<tr>
<td>Other agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baclofen</td>
<td>5 mg</td>
<td>Neuropathic pain, muscle spasms</td>
<td>Probable increased sensitivity and decreased clearance</td>
<td>Monitor for weakness, urinary dysfunction; avoid abrupt discontinuation due to CNS irritability</td>
</tr>
</tbody>
</table>

CBC = complete blood count; CNS = central nervous system; ECG = electrocardiogram; HS = hour of sleep or at bedtime; LFT = liver function tests; RF = renal function.
cesses at some level. Economic considerations should be used to make balanced decisions after sound principles of assessment and treatment have been followed. Clinicians should be aware of common economic barriers patients and their families may encounter, including the lack of Medicare reimbursement for outpatient oral medications, limited formulas, and delays from mail-order pharmacies in some managed-care programs, as well as limited availability of strong opioid analgesics from some pharmacies.

Finally, it is axiomatic that all medication management must be tailored to the individual patient’s needs and situations. Information provided herein is meant to serve as a guide only and should not be used in lieu of clinical judgment.

Specific Recommendations

I. All older patients with diminished quality of life as a result of chronic pain are candidates for pharmacologic therapy.

II. The least invasive route of administration should be used (this is usually the oral route).

III. Fast-onset, short-acting analgesic drugs should be used for episodic (i.e., chronic recurrent or noncontinuous) pain.

IV. Acetaminophen is the drug of choice for relieving mild to moderate musculoskeletal pain. The maximum dosage of acetaminophen should not exceed 4000 mg per day.

V. NSAIDs should be used with caution.
   A. High-dose, long-term NSAID use should be avoided.
   B. When used chronically, NSAIDs should be used as needed, rather than daily or around the clock.
   C. Short-acting NSAIDs may be preferable to avoid dose accumulation.
   D. NSAIDs should be avoided in patients with abnormal renal function.
   E. NSAIDs should be avoided in patients with a history of peptic ulcer disease.
   F. NSAIDs should be avoided in patients with a bleeding diathesis.
   G. The use of more than one NSAID at a time should be avoided.
   H. Ceiling dose limitations should be anticipated (i.e., maximum dose may be unattainable because of toxicity or may be accompanied by lack of efficacy).

VI. Opioid analgesic drugs may be helpful for relieving moderate to severe pain, especially nociceptive pain.
   A. Opioids for episodic (i.e., chronic recurrent or noncontinuous) pain should be prescribed as needed, rather than around the clock.
   B. Long-acting or sustained-release analgesic preparations should be used only for continuous pain.
   1. Breakthrough pain should be identified and treated by the use of fast-onset, short-acting preparations. Breakthrough pain includes the following three types:
      a. End-of-dose failure is the result of decreased blood levels of analgesic with concomitant increase in pain before the next scheduled dose.
      b. Incident pain is usually caused by activity that can be anticipated and pretreated.
      c. Spontaneous pain, common with neuropathic pain, is often fleeting and difficult to predict.
   2. Titration should be conducted carefully.
      a. Titration should be based on the persistent need for and use of medications for breakthrough pain.
      b. Titration should be based on the pharmacokinetics and pharmacodynamics of specific drugs in the older person and the propensity for drug accumulation.
      c. The potential adverse effects of opioid analgesic medication should be anticipated and prevented or treated promptly.
   3. Constipation should be prevented.
      a. A prophylactic bowel regimen should be initiated with commencement of analgesic therapy.
      b. Bulking agents should be avoided.
      c. Adequate fluid intake should be encouraged.
      d. Exercise, ambulation, and physical activities should be encouraged.
      e. Bowel function should be evaluated with every follow-up visit.
      f. Rectal examination and disimpaction should occur before use of motility agents.
      g. An osmotic, stimulant, or motility agent should be prescribed, if necessary, to provide regular bowel evacuation.
      h. Motility agents should not be used if signs or symptoms of obstruction are present.
      i. If fecal impaction is present, it should be relieved by enema or manual removal.

4. Mild sedation and impaired cognitive performance should be anticipated when opioid analgesic drugs are initiated. Until tolerance for these effects has developed:
   a. patients should be instructed not to drive.
   b. patients and caregivers should be cautioned about the potential for falls and accidents.
   c. monitoring for profound sedation, unconsciousness, or respiratory depression (defined as a respiratory rate of <8 per minute or oxygen saturation of <90%) should occur during rapid, high-dose escalations. Naloxone should be used carefully to avoid abrupt reversal of pain and autonomic crisis.

5. Severe nausea may need to be treated with antiemetic medications, as needed.
   a. Mild nausea usually resolves spontaneously in a few days.
   b. If nausea persists, a trial of an alternative opioid may be appropriate.
   c. Anti-emetic drugs should be chosen from those with the lowest side-effect profiles in older persons.
VI. Fixed-dose combinations (e.g., acetaminophen and opioid) may be used for mild to moderate pain.
A. Maximum recommended dose should not be exceeded to minimize toxicity of acetaminophen or NSAID.
B. Ceiling effect should be anticipated (i.e., maximum dose may be reached without full efficacy because of limits imposed by toxicity of acetaminophen or an NSAID).

VIII. Patients taking analgesic medications should be monitored closely.
A. Patients should be re-evaluated frequently for drug efficacy and side effects during initiation, titration, or any change in dose of analgesic medications.
B. Patients should be re-evaluated on a regular basis for drug effectiveness and side effects throughout long-term analgesic drug maintenance.
1. Patients on long-term opioid therapy should be evaluated periodically for inappropriate or even dangerous drug-use patterns.
   a. The clinician should watch for indications of the use of medications prescribed for other persons or of illicit drug use (the latter being very rare in this population).
   b. The clinician should ask about prescriptions for opioids from other physicians.
   c. The clinician should watch for signs of narcotic use for inappropriate indications (e.g., anxiety, depression).
   d. Requests for early refills should include evaluation of tolerance, progressive disease, or inappropriate behavioral factors.
   e. These evaluations need to take place with the same medical equanimity accompanying similar evaluations for long-term management of other potentially risky medications (i.e., antihypertensive medications) in order not to burden the patient with excessive worry or unnecessary fears, or to promote “opiophobia.”
2. Patients on long-term NSAIDs should be periodically monitored for gastrointestinal blood loss, renal insufficiency, and other drug-drug or drug-disease interactions.

IX. Non-opioid analgesic medications may be appropriate for some patients with neuropathic pain and some other chronic pain syndromes.
A. Carbamazepine is the medication of choice for trigeminal neuralgia.
B. Agents with the lowest side-effect profiles should be chosen preferentially.
C. Agents may be used alone but often are more helpful when used in combination and to augment other pain management strategies.
D. Therapy should begin with the lowest possible doses and increased slowly because of the potential for toxicity of many agents.
E. Patients should be monitored closely for side effects.
F. Clinical endpoints should be decreased pain, increased function, improvements in mood and sleep, not decreased drug dose.

NONPHARMACOLOGIC STRATEGIES FOR PAIN MANAGEMENT IN OLDER PERSONS

General Principles
Nonpharmacologic approaches, used alone or in combination with appropriate pharmacologic strategies, should be an integral part of care plans for most chronic pain patients. Nonpharmacologic pain management strategies encompass a broad range of treatments and physical modalities. Education programs, cognitive-behavioral therapy, exercise programs, acupuncture, transcutaneous nerve stimulation, chiropractic, heat, cold, massage, relaxation, and distraction techniques have each been helpful for some patients. Moreover, these strategies carry few adverse effects other than cost. Many patients use these approaches, not always with the advice of their primary healthcare provider. Although many of these interventions provide short-term relief, few have been shown to have greater benefit than placebo controls in randomized trials for the long-term management of chronic pain in older people. Nonetheless, nonpharmacologic interventions used in combination with appropriate drug regimens often improve overall pain management, enhancing therapeutic effects while allowing reduction of medication doses to prevent or diminish adverse drug effects.

A variety of alternative therapies are also used by many patients. Healthcare providers should be aware that patients with unrelieved chronic pain often seek alternative medicine approaches, including use of homeopathy, naturopathic preparations, and spiritual healing. Although there is little scientific evidence to support these strategies for chronic pain control, it is important that healthcare providers not leave patients with a sense of hopelessness in an effort to discourage unapproved but benign therapies or to debunk healthcare quackery and fraud.

The importance of patient education cannot be overemphasized. Studies have shown that patient education programs alone significantly improve overall pain management. Such education programs commonly include information about the nature of pain and how to use pain assessment instruments, medications, and nonpharmacologic pain management strategies. For many patients, especially older persons, family caregiver education is also essential. Whether the program is conducted one-on-one or organized in groups, it should be tailored to patients’ needs and levels of understanding. The use of suitable written materials and appropriate methods for reinforcement is important to the success of the program.

Cognitive strategies are aimed at altering belief structures, attitudes, and thoughts in order to modify the experience of pain and suffering. These include various forms of distraction, relaxation, biofeedback, and hypnosis. Behavioral therapy discourages abnormal, unpredictable, or self-defeating behavior and provides positive reinforcement for successes in achieving goals. Cognitive strategies are usually
combined with behavioral approaches, and together they are known as cognitive-behavioral therapy. Cognitive-behavioral therapy in its most effective form includes a structured approach to teaching coping skills that might be used alone or in combination with pharmacologic therapies for chronic pain control. Effective programs can be conducted with patients individually or in groups. There is some evidence that the involvement of a spouse, caregiver, or significant other enhances the effects. Cognitive-behavioral therapy usually requires 6 to 15 sessions (60 to 90 minutes per session) with a trained therapist and includes components of education, rationale for therapy, coping skills training, methods to generalize coping skills, and relapse prevention. Although it may not be appropriate for patients with appreciable cognitive impairment, the favorable results of controlled trials support the use of cognitive-behavioral therapy as a part of the management of most patients with significant chronic pain.

Physical exercise has also been shown to improve pain management in older patients significantly. Clinical trials involving older patients with chronic musculoskeletal pain have shown that moderate levels of training (aerobic and resistance training) on a regular basis are effective in improving pain and functional status. Initial training usually requires 8 to 12 weeks and supervision by a knowledgeable professional who can focus on the special needs of older adults with musculoskeletal conditions. There is no evidence that one type of exercise is better than another; thus, the exercise program should be tailored to the needs and preferences of the patient. The intensity, frequency, and duration should be adjusted to avoid exacerbation of pain while increasing and later maintaining overall conditioning. Feeling better may give the false impression that the discipline of ongoing self-directed exercise is no longer necessary. Continual encouragement and reinforcement is often necessary. Unless contraindications supervene, the program should be maintained indefinitely to prevent deconditioning and deterioration.

Specific Recommendations

I. All patients with diminished quality of life as a result of chronic pain are candidates for nonpharmacologic pain management strategies.

II. Patient education should be provided for all patients with chronic pain.
   A. Content should include information about the known cause(s) of pain, methods of pain assessment and measurement, goals of treatment, treatment options, expectations of pain management, analgesic drug use for pain management (prescription and over-the-counter medications), and self-help techniques, such as the use of heat, cold, massage, relaxation, and distraction.
   B. Educational content should be reinforced during every patient encounter.
   C. Specific patient education should be provided before special treatments or procedures.

III. Nonpharmacologic interventions can be used alone or in combination with pharmacologic strategies for chronic pain management.

IV. Cognitive-behavioral therapies should be a part of the care of older patients troubled by chronic pain.
   A. Cognitive-behavioral therapy should be applied as a structured program that includes components of education, rationale for therapy, coping skills training, methods to generalize coping skills, and relapse prevention.
   B. Cognitive-behavioral therapy should be conducted by a professional.
   C. Plans for a flare-up should be a part of this therapy to prevent self-defeating behavior during episodes of pain exacerbation.

V. Exercise should be a part of the care of all older patients troubled by chronic pain.
   A. Initial training should be conducted over 8 to 12 weeks and should be supervised by a trained professional with knowledge of the special needs of older adults.
   B. Exercise should be tailored to the needs and preferences of the patient in consultation with the primary clinician.
   C. Moderate levels of exercise conditioning (aerobic or resistance training) should be maintained indefinitely.

VI. A trial of physical or occupational therapy is appropriate for the rehabilitation of impaired range of motion, specific muscle weakness, or other physical impairments associated with chronic pain.

VII. Traditional insight-oriented psychotherapy should not be used alone for the management of chronic pain.

VIII. Other nonpharmacologic therapies may be helpful for some patients with chronic pain.
   A. Chiropractic, acupuncture, or transcutaneous nerve stimulation may be helpful for some patients, but they are expensive and have not been shown to have greater benefit than placebo controls in the management of chronic pain. These interventions should be provided only by professionals.
   B. Self-administered heat, cold, and massage and the use of liniments and other topical agents may be helpful for some patients.
      1. Initial instruction and demonstration should be provided by a trained clinician.
      2. Precautions against thermal injury should be provided, especially for patients with sensory disturbances (e.g., diabetic patients) or with cognitive impairment.
      3. Patients should be cautioned about the toxicity of or possible reactions to liniments and other topical agents.

RECOMMENDATIONS FOR HEALTH SYSTEMS THAT CARE FOR OLDER PERSONS

General Principles

The United States healthcare system is probably the most complex in the world. Access to and delivery of quality health care vary considerably, depending on economic and social priorities in each of the 50 states. Medical care is provided by a large number of independent for-profit and not-for-profit healthcare businesses, including ambulatory care facilities,
hospitals, nursing homes, and home-health agencies. Free-standing pharmacies, emergency services, and a variety of other community services contribute substantially to the quality of the American healthcare system. Because of the growing population of older people, many of whom have chronic illnesses, almost every component of the U.S. healthcare system can be expected to care for a substantial number of older patients with chronic pain.

The healthcare system has an obligation to provide comfort and pain management for older patients. Healthcare facilities, quality review organizations, and government regulatory agencies should work together to facilitate structures and processes that ensure access and delivery of quality pain management services. In some cases, organizations need to revise existing regulations that have actually created barriers to effective pain management. Medical license boards and law enforcement agencies, in their efforts to reduce illicit drug use, should recognize their equal obligation to ensure the easy availability of safe and effective pain medications (i.e., opioid analgesic drugs) for those with legitimate medical needs.115

Traditionally, healthcare professionals have not been adequately trained in pain assessment and management.110–116 This lack of sensitivity to the problem of pain and its sequelae has contributed to both underrecognition and undertreatment of pain in older adults. Progress has been limited by a lack of professional attention to the interdisciplinary model critical to effective care of older adults. Refocusing not only the curricula for trainees but also continuing education for healthcare professionals is the key to assuring optimum care for older adults. Using such education as an indicator of quality by healthcare organizations and accreditation bodies will serve to more fully integrate the principles of pain management into clinical practice. Likewise, empowering consumers with an appreciation of the principles of pain management will create an advocacy for standards by which all providers will eventually be measured.

Today, financial considerations are a part of every healthcare decision. Insurance companies, managed care plans, and federal and state health agencies should recognize the importance of pain management. Adequate reimbursement should be provided for those services that ensure comfort, rehabilitation, and palliative care, especially for those near the end of life. Third-party payers need to consider carefully the financial incentives they create. Policies that favor expensive procedures appropriate for only a few patients may result in needless suffering for many patients. Although these policies may seem financially prudent in the short term, they may result in needless disability and increased health care utilization in the long run.

Specific Recommendations

I. Health care facilities should support policies and procedures for routine screening, assessment, and treatment of chronic pain among all older patients. Health organizations should include pain management as a major domain in the development of clinical pathways.

II. Healthcare facilities (ambulatory care facilities, hospitals, nursing homes, and home-care agencies) should periodically conduct quality assurance or quality improvement (QA or QI) activities in pain management.

A. QA or QI activities should include appropriate structure and process indicators of pain assessment and treatment activities.

B. Benchmarks for quality improvement should be established internally and should include quantifiable pain outcomes, including (but not limited to) patient satisfaction.

III. Healthcare financing systems (third-party payers, managed care organizations, and publicly financed programs) should extend resources for chronic pain management.

A. Present diagnosis-driven reimbursement systems should be revised to improve incentives for pain management and symptom control.

1. Effective pharmacologic and nonpharmacologic strategies for pain management should be provided.

2. Cost-containment strategies must not result in the inaccessibility of effective treatment or needless suffering.

B. Reimbursement should be appropriate for the increased time and resources often necessary for the care of frail, dependent, and disabled older patients in all settings.

IV. Health systems (integrated networks and community health planners) should ensure accessibility to specialty pain services.

V. Specialty pain services should be accredited and adhere to guidelines defined by quality review organizations.

VI. Pain-management education for all health care professionals should be improved at all levels.

A. Professional health school curricula should provide substantial training and experience in chronic pain management in older adults.

1. Curricula should adhere to curriculum guidelines established by the International Association for the Study of Pain (IASP).

2. Trainees should demonstrate proficiency in pain assessment and management.

B. Health systems should provide continuing education in pain assessment and management to health professionals at all levels.

C. Accreditation bodies should include pain management curriculum content as evaluation criteria.

D. Pain management should be included in consumer information services.

VII. Programs and regulations designed to decrease illicit drug use should be revised to eliminate barriers to chronic pain management for the older patient.

A. State medical license boards should publish professional standards or guidelines for prescribing controlled substances for pain, including professional standards for chronic use, expectations for medical record documentation, and standards for professional conduct review.

B. State medical license boards must eliminate clinicians’ trepidation over conduct review that has become a major barrier to the prescription of effective medications.
C. Law and drug enforcement agencies should recognize their role in facilitating and providing easy access to the legitimate use of controlled substances for patients in pain.

D. Law and drug enforcement agencies should publish information for clinicians and the public regarding legal and illegal prescribing, dispensing, storage, disposal, and use of controlled substances for pain management.

ACKNOWLEDGMENTS

The American Geriatrics Society (AGS) Panel on Chronic Pain in Older Persons includes: Bruce A. Ferrell, MD (Chairman); UCLA School of Medicine and Sepulveda VA Geriatric Research Education & Clinical Center (GRECC), Los Angeles, CA; Laurence A. Bradley, PhD: University of Alabama at Birmingham School of Medicine, Birmingham, AL; Leo M. Cooney, Jr., MD: Yale University School of Medicine, New Haven, CT; Walter H. Ettinger, Jr., MD, MBA: Wake Forest University School of Medicine, Center on Aging, Winston Salem, NC; Perry G. Fine, MD: University of Utah Pain Management Center and Vista Care, Salt Lake City, UT; Keela Herr, PhD, RN, CS: College of Nursing, The University of Iowa, Iowa City, IA; Benny Katz, MBBS, FRACP, PhD: National Ageing Research Institute and Pain Management Centre, North West Hospital, Parkville, Victoria, Australia; Paul R. Katz, MD: University of Rochester School of Medicine, Rochester, NY; D. Joanne Lynn, MD, MA, MS: Center to Improve Care of the Dying, George Washington University, Washington, DC; Janice B. Schwartz, MD: Northwestern University School of Medicine, Chicago, IL; Patricia Connelly: Senior Director, Special Projects and Education, American Geriatrics Society, New York, NY.

Research services were provided by Meredith Wallace, MS, RN, The John A. Hartford Foundation Institute for the Advancement of Geriatric Nursing Practice, NYU Division of Nursing, New York, NY. Editorial services were provided by Barbara B. Reitt, PhD, ELS(D), Reitt Editing Services, Highlands, NC. Additional research and administrative support was provided by Janis Eissner, Nancy Lundeberg, and Gloria Orraca, Department of Special Projects, American Geriatrics Society, New York, NY.

The following organizations with special interest and expertise in the management of pain in older persons provided peer review of a preliminary draft of these guidelines: American Academy of Pain Medicine; American Academy of Physical Medicine and Rehabilitation; American College of Clinical Pharmacy; American College of Rheumatology; American Medical Directors Association; American Pain Society; American Society of Consultant Pharmacists; Gerontological Society of America; Oncology Nursing Society.

The development of these guidelines was supported by an educational grant from the McNeil Consumer Products Company.

REFERENCES